```
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:52:33 ON 04 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    3 NOV 2005  HIGHEST RN 866718-46-9
DICTIONARY FILE UPDATES:   3 NOV 2005  HIGHEST RN 866718-46-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-684537.str
```



```
chain nodes :
15  17  18  22
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14
```

```
chain bonds :
1-22  6-15  9-15  15-17  17-18
ring bonds :
1-2  1-6  2-3  2-14  3-4  4-5  5-6  5-13  7-8  7-12  8-9  9-10  10-11  11-12  13-14

exact/norm bonds :
1-2  1-6  1-22  2-3  2-14  3-4  4-5  5-6  5-13  6-15  9-15  13-14  17-18
exact bonds :
15-17
normalized bonds :
7-8  7-12  8-9  9-10  10-11  11-12
isolated ring systems :
containing 1 : 7 :


G1:H,Ak

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:CLASS  17:CLASS  18:Atom  22:CLASS




L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```



```
G1 H,Ak


Structure attributes must be viewed using STN Express query preparation.


=> s l1 ful
FULL SEARCH INITIATED 17:53:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1764 TO ITERATE

100.0% PROCESSED     1764 ITERATIONS                           42 ANSWERS
SEARCH TIME: 00.00.01

L2           42 SEA SSS FUL L1
```

```
=> fil caplus
COST IN U.S. DOLLARS                                 SINCE FILE       TOTAL
                                                          ENTRY     SESSION
FULL ESTIMATED COST                                      161.33      161.54

FILE 'CAPLUS' ENTERED AT 17:53:08 ON 04 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Nov 2005  VOL 143 ISS 20
FILE LAST UPDATED: 3 Nov 2005  (20051103/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3            2 L2

=> d fbib abs hitstr tot
```

```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:354937  CAPLUS
DN   140:357537
TI   Preparation of substituted aminoquinuclidines for use in pharmaceutical
     compositions as δ-opioid receptor modulators
IN   Boyd, Robert E.; Reitz, Allen B.
PA   Janssen Pharmaceutica, N.V., Belg.
SO   PCT Int. Appl., 47 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.         DATE
     ---------------     ----   --------   --------------------    --------
PI   WO 2004035574        A2    20040429   WO 2003-US32221         20031014
     WO 2004035574        A3    20040603
     WO 2004035574        C1    20040729
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                       US 2002-418603P      P  20021015
     CA 2501552           AA    20040429   CA 2003-2501552         20031014
                                       US 2002-418603P      P  20021015
                                       WO 2003-US32221      W  20031014
     US 2004110789        A1    20040610   US 2003-684537          20031014
                                       US 2002-418603P      P  20021015
     EP 1558610           A2    20050803   EP 2003-776299          20031014
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                       US 2002-418603P      P  20021015
                                       WO 2003-US32221      W  20031014
OS   MARPAT 140:357537
GI
```



I



II

```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN     (Continued)
AB   This invention is directed toward the preparation of quinuclidinyl
substituted
     benzamides, such as I [R = aryl, heteroaryl; R2 = H, alkyl; R3 = H, OH,
     CN, NO2, NH2, halogen, alkyl, alkoxy, alkylamino, carboxy, carboxamido,
     alkylsulfonyl, etc.; X = -(CH2)n-; Y = O, S; Z = NR4R5; R4, R5 = H,
alkyl,
     alkenyl, aryl, cycloalkyl, etc.; NR4R5 = N bonded heterocyclic ring, such
     as 1-pyrrolidinyl, or 4-morpholinyl; n = 0-2], for therapeutic use as
     δ-opioid receptor modulators.  The prepared benzamides are claimed for
     therapeutic use as δ-opioid receptor agonists useful as analgesics
     and as δ-opioid receptor antagonists useful as immunosuppressants,
     anti-inflammatory agents.  Further, these benzamides are claimed for use
     in the treatment of immune disorders, inflammation, neurol. conditions,
     psychiatric conditions, drug abuse, alc. abuse, gastritis, diarrhea,
     cardiovascular disorders and respiratory disorders which can be modulated
     by a therapeutically effective amount of a δ-opioid receptor
     antagonist.  Thus, quinuclidinyl benzamide II as a fumarate salt was
     prepared via a synthetic sequence which included reacting
     1-azabicyclo[2.2.2]octan-3-one with aniline using Ti(OPr-i)4 followed by
     NaBH4 in EtOH to give N-phenyl-1-azabicyclo[2.2.2]octan-3-amine in 75%
     yield, and subsequent reaction of the amine with 4-bromo-N,N-
     diethylbenzamide using Pd2(dba)3, BINAP and tert-BuONa in toluene and,
     finally salt formation using fumaric acid to give II.fumarate salt with
     37% yield for the last step.  The prepared quinuclidinyl benzamides were
     assayed for δ-opioid receptor binding activity using rat brain
     tissue.
IT   682777-67-9P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of quinuclidinyl benzamides for use in pharmaceutical
compns.
        as δ-opioid receptor modulators)
RN   682777-67-9  CAPLUS
CN   Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl(3-methoxyphenyl)amino]-N,N-
     diethyl-, (2E)-2-butenedioate (1:1) (9CI)  (CA INDEX NAME)

     CM   1

     CRN  682777-66-8
     CMF  C25 H33 N3 O2
```



```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN     (Continued)

     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
IT   682777-62-4P 682777-75-9P 682777-78-2P
     682777-82-8P 682777-84-0P 682777-86-2P
     682777-89-5P 682777-96-4P 682777-99-7P
     682778-05-8P 682778-10-5P 682778-15-0P
     682778-20-7P 682778-24-1P 682778-28-5P
     682778-34-3P 682778-41-2P 682778-47-8P
     682778-55-8P 682778-63-8P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of quinuclidinyl benzamides for use in pharmaceutical
compns.
        as δ-opioid receptor modulators)
RN   682777-62-4  CAPLUS
CN   Benzamide, 4-(1-azabicyclo[2.2.2]oct-3-ylphenylamino)-N,N-diethyl-,
     (2E)-2-butenedioate (1:1) (9CI)  (CA INDEX NAME)

     CM   1

     CRN  682777-61-3
     CMF  C24 H31 N3 O
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682777-75-9  CAPLUS
CN   Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl(3-hydroxyphenyl)amino]-N,N-
     diethyl-, (2E)-2-butenedioate (1:1) (salt) (9CI)  (CA INDEX NAME)
```

```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN     (Continued)
     CM   1

     CRN  682777-74-8
     CMF  C24 H31 N3 O2
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682777-78-2  CAPLUS
CN   Benzamide,
4-[1-azabicyclo[2.2.2]oct-3-yl[3-(trifluoromethyl)phenyl]amino]-
     N,N-diethyl-, monohydrochloride (9CI)  (CA INDEX NAME)
```



● HCl

```
RN   682777-82-8  CAPLUS
CN   Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl(2-methoxyphenyl)amino]-N,N-
     diethyl-, monohydrochloride (9CI)  (CA INDEX NAME)
```



● HCl

RN 682777-84-0 CAPLUS
CN Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl(3-chlorophenyl)amino]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 682777-86-2 CAPLUS
CN Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl(3,5-dichlorophenyl)amino]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 682777-89-5 CAPLUS
CN Benzamide, N,N-diethyl-4-[[(2R,3S)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]phenylamino]-, rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 682777-88-4
CMF C25 H33 N3 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 682777-96-4 CAPLUS
CN Benzamide, N,N-diethyl-4-[[(2R,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]phenylamino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 682777-99-7 CAPLUS
CN Benzamide,
N,N-diethyl-4-[[(2R,3S)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl][3-(methylthio)phenyl]amino]-, rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 682777-98-6
CMF C26 H35 N3 O S

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 682778-05-8 CAPLUS
CN Benzamide,
4-(1-azabicyclo[2.2.2]oct-3-ylphenylamino)-N,N-diethyl-2-fluoro-

, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 682778-04-7
CMF C24 H30 F N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 682778-10-5 CAPLUS
CN Benzamide,
4-(1-azabicyclo[2.2.2]oct-3-ylphenylamino)-N,N-diethyl-2-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 682778-09-2
CMF C25 H33 N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN      (Continued)
RN   682778-15-0  CAPLUS
CN   Benzamide,
4-(1-azabicyclo[2.2.2]oct-3-ylphenylamino)-2-chloro-N,N-diethyl-
     , (2E)-2-butenedioate (1:1)  (9CI)   (CA INDEX NAME)

     CM   1

     CRN  682778-14-9
     CMF  C24 H30 Cl N3 O
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-20-7  CAPLUS
CN   Pyrrolidine, 1-[4-[1-azabicyclo[2.2.2]oct-3-yl(4-
     methoxyphenyl)amino]benzoyl]-, (2E)-2-butenedioate (1:1)  (9CI)   (CA INDEX
     NAME)

     CM   1

     CRN  682778-19-4
     CMF  C25 H31 N3 O2
```



```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN      (Continued)

     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-24-1  CAPLUS
CN   Morpholine, 4-[4-(1-azabicyclo[2.2.2]oct-3-ylphenylamino)benzoyl]-,
     (2E)-2-butenedioate (1:1)  (9CI)   (CA INDEX NAME)

     CM   1

     CRN  682778-23-0
     CMF  C24 H29 N3 O2
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-28-5  CAPLUS
CN   Benzamide,
4-[1-azabicyclo[2.2.2]oct-3-yl(phenylmethyl)amino]-N,N-diethyl-
     , (2E)-2-butenedioate (1:1)  (9CI)   (CA INDEX NAME)

     CM   1

     CRN  682778-27-4
     CMF  C25 H33 N3 O
```

```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN      (Continued)
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-34-3  CAPLUS
CN   Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl[(3-chlorophenyl)methyl]amino]-
     N,N-diethyl-, (2E)-2-butenedioate (1:1)  (9CI)   (CA INDEX NAME)

     CM   1

     CRN  682778-33-2
     CMF  C25 H32 Cl N3 O
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-41-2  CAPLUS
```

```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN      (Continued)
CN   Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl[(2-fluorophenyl)methyl]amino]-
     N,N-diethyl-, (2E)-2-butenedioate (1:1)  (9CI)   (CA INDEX NAME)

     CM   1

     CRN  682778-40-1
     CMF  C25 H32 F N3 O
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-47-8  CAPLUS
CN   Benzamide, 4-[1-azabicyclo[2.2.2]oct-3-yl[(3-fluorophenyl)methyl]amino]-
     N,N-diethyl-, (2E)-2-butenedioate (1:1)  (9CI)   (CA INDEX NAME)

     CM   1

     CRN  682778-46-7
     CMF  C25 H32 F N3 O
```

```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN      (Continued)
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-55-8  CAPLUS
CN   Benzamide, 4-[(3R)-1-azabicyclo[2.2.2]oct-3-yl(phenylmethyl)amino]-N,N-
     diethyl-, (2E)-2-butenedioate (1:1) (9CI)  (CA INDEX NAME)

     CM   1

     CRN  682778-54-7
     CMF  C25 H33 N3 O

Absolute stereochemistry.
```



```
     CM   2

     CRN  110-17-8
```

```
L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN      (Continued)
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
RN   682778-63-8  CAPLUS
CN   Benzamide, 4-[(3S)-1-azabicyclo[2.2.2]oct-3-yl(phenylmethyl)amino]-N,N-
     diethyl-, (2E)-2-butenedioate (1:1) (9CI)  (CA INDEX NAME)

     CM   1

     CRN  682778-62-7
     CMF  C25 H33 N3 O

Absolute stereochemistry.
```



```
     CM   2

     CRN  110-17-8
     CMF  C4 H4 O4

Double bond geometry as shown.
```



```
L3   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2002:754380  CAPLUS
DN   137:263071
TI   Preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as
     anti-telomerase agents
IN   Mailliet, Patrick; Laoui, Abdelazize; Riou, Jean-Francois; Doerflinger,
     Gilles; Mergny, Jean-Louis; Hamy, Francois; Caulfield, Thomas
PA   Aventis Pharma S.A., Fr.
SO   PCT Int. Appl., 208 pp.
     CODEN: PIXXD2
DT   Patent
LA   French
FAN.CNT 1
     PATENT NO.          KIND    DATE         APPLICATION NO.         DATE
     ---------------     ----    --------     --------------------    --------
PI   WO 2002076975        A1     20021003     WO 2002-FR1005          20020322
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                              FR 2001-3916         A  20010323
                                              FR 2001-10370        A  20010802
                                              US 2001-332009P      P  20011123
     FR 2822468           A1     20020927     FR 2001-3916            20010323
     CA 2442012           AA     20021003     CA 2002-2442012         20020322
                                              FR 2001-3916         A  20010323
                                              FR 2001-10370        A  20010802
                                              WO 2002-FR1005       W  20020322
     EP 1373252           A1     20040102     EP 2002-720068          20020322
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                              FR 2001-3916         A  20010323
                                              FR 2001-10370        A  20010802
                                              WO 2002-FR1005       W  20020322
     JP 2004524349        T2     20040812     JP 2002-576233          20020322
                                              FR 2001-3916         A  20010323
                                              FR 2001-10370        A  20010802
                                              WO 2002-FR1005       W  20020322
     US 2003087931        A1     20030508     US 2002-103883          20020325
     US 6887873           B2     20050503
                                              FR 2001-3916         A  20010323
                                              FR 2001-10370        A  20010802
                                              US 2001-332009P      P  20011123
     US 2005070571        A1     20050331     US 2004-993637          20041119
                                              FR 2001-3916         A  20010323
                                              FR 2001-10370        A  20010802
                                              US 2001-332009P      P  20011123
                                              US 2002-103883       A3 20020325
OS   MARPAT 137:263071
GI
```

```
L3   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN      (Continued)
```



I



II

```
AB   Title compds. I [A = XR1R2; X = N, O, S, alkyl radical; R1-2 = H, alkyl,
     heterocyclyl, etc.; R3-3' = H, alkyl, isoquinolinyl, quinolinyl, etc.;
     Ar1-2 = (un)substituted Ph, etc., and derivs. thereof] were prepared  For
     instance, 2,4-bis[(4-(dimethylamino)-2-methylquinolin-6-yl)amino]-6-
     chloro[1,3,5]triazine (prior art) was reacted with N,N-dimethyl-1,3-
     propanediamine in DMF with K2CO3 for 15 h at 100° to afford II.
     Examples include evaluation of all compds. of the invention for
telomerase
     activity.  I are anti-cancer agents.
IT   462650-93-7P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as
        anti-telomerase agents)
RN   462650-93-7  CAPLUS
CN   1,3,5-Triazine-2,4,6-triamine,
N-1-azabicyclo[2.2.2]oct-3-yl-N',N''-bis[4-
     (dimethylamino)-2-methyl-6-quinolinyl]-N-phenyl- (9CI)  (CA INDEX NAME)
```

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT